SELLAS Life Sciences Group, Inc.
NASDAQTotal Valuation
SELLAS Life Sciences Group, Inc. carries a market capitalization of 2.40B, placing it among publicly traded companies globally. Its enterprise value stands at 428.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.40B |
| Enterprise Value | 428.78M |
Share Statistics
SELLAS Life Sciences Group, Inc. currently has 181.33M shares outstanding.
| Shares Outstanding | 181.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.89 |
| P/TBV Ratio | 5.07 |
| P/FCF Ratio | -19.00 |
| P/OCF Ratio | -19.00 |
Financial Position
SELLAS Life Sciences Group, Inc. maintains a current ratio of 17.22, meaning it holds 17.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.22 |
| Quick Ratio | 16.59 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
SELLAS Life Sciences Group, Inc.'s stock has gained approximately 601.08696% over the past 52 weeks. The 50-day moving average sits at 9.76, while the 200-day moving average is 5.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | 601.08696% |
| 50-Day Moving Average | 9.76 |
| 200-Day Moving Average | 5.04 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -31.46M, while operating income came in at -31.46M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -31.46M |
| Pretax Income | -29.46M |
| Net Income | -29.46M |
| EBITDA | -31.46M |
| EBIT | -31.46M |
| Earnings Per Share (EPS) | -0.23 |
Balance Sheet
SELLAS Life Sciences Group, Inc. holds 107.10M in cash and equivalents against 871,000.00 in total debt, resulting in a net debt position of -107.10M. Total book value stands at -283.38M, with working capital of 104.71M providing operational flexibility.
| Cash & Cash Equivalents | 107.10M |
| Total Debt | 871,000.00 |
| Net Debt | -107.10M |
| Equity (Book Value) | -283.38M |
| Book Value Per Share | -2.24 |
| Working Capital | 104.71M |
Cash Flow
SELLAS Life Sciences Group, Inc. produced -28.16M in operating cash flow over the past twelve months.
| Operating Cash Flow | -28.16M |
| Capital Expenditures | N/A |
| Free Cash Flow | -28.16M |
| FCF Per Share | -0.22 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -19.97 |
| FCF Yield | -5.26 |
Stock Splits
SELLAS Life Sciences Group, Inc.'s most recent stock split took place on November 8, 2019 with a 50:1 split ratio.
| Last Split Date | 11/8/2019 |
| Split Ratio | 50:1 |
Scores
SELLAS Life Sciences Group, Inc. posts an Altman Z-Score of 44.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 44.11 |